S&P ASX All Technology

US Dollar vs AUD

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

LPTX Leap Therapeutics Inc

3.55

0.00 (0.00%)

06 Nov 2024 - Closed

Delayed by 15 minutes

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Leap Therapeutics (NASDAQ:LPTX)
Historical Stock Chart
From Oct 2024 to Nov 2024

Click Here for more Leap Therapeutics Charts.

Leap Therapeutics (NASDAQ:LPTX)
Historical Stock Chart
From Nov 2023 to Nov 2024

Click Here for more Leap Therapeutics Charts.

Leap Therapeutics Inc News

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
Friday 1 November 2024 (5 days ago) • Edgar (US Regulatory)

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
Friday 1 November 2024 (5 days ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Saturday 5 October 2024 (1 month ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Saturday 5 October 2024 (1 month ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Saturday 5 October 2024 (1 month ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Saturday 5 October 2024 (1 month ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Saturday 5 October 2024 (1 month ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Saturday 5 October 2024 (1 month ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Saturday 5 October 2024 (1 month ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Saturday 5 October 2024 (1 month ago) • Edgar (US Regulatory)

Form 8-K - Current report
Monday 30 September 2024 (1 month ago) • Edgar (US Regulatory)

Leap Therapeutics Announces Completion of Enrollment in Part B of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients
Monday 30 September 2024 (1 month ago) • PR Newswire (US)

More Leap Therapeutics Inc News Articles

AUD vs US Dollar

Invesco QQQ Trust Series 1

Gold vs US Dollar

Westpac Banking

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions